The personalized cancer-vaccine frontier. See how it all connects.

Follow how tumor sequencing, AI and computational tools, vaccine design, manufacturing, clinical trials, and access fit together.

Get the Tuesday field note Navigate the system
Conceptual editorial still life of a pathology slide, an analysis sheet, and a folded RNA model arranged from left to right
  1. 01Tumor sample
  2. 02Target selection
  3. 03Vaccine design
From one tumor to an individualized design. Conceptual editorial artwork; exact research workflows differ by platform and study.

From one tumor to an individualized vaccine.

Personalized vaccine programs can connect tumor sequencing, computational target selection, a custom vaccine design, manufacturing, and clinical study. Each step answers a different question; finding a promising target is only the beginning.

Tumor

Tumor material—and often a normal comparison—provides the starting data.

Sequence

DNA and sometimes RNA data help identify tumor-specific changes.

Rank

Algorithms and machine-learning tools prioritize candidate neoantigens for further study.

Design

Selected targets are encoded or formulated using a product-specific vaccine platform.

Build

An individualized product is manufactured and tested under a study or program process.

Learn

Researchers measure feasibility, immune response, safety, and clinical outcomes as separate results.

Conceptual path only; methods differ by platform and study. Read the NCI neoantigen definition and a peer-reviewed overview of individualized vaccine target discovery. On a phone, swipe across the connected sheet.

Where AI enters the personalized-vaccine story.

Researchers use computational methods to sift through tumor mutations and rank potential neoantigens. ImmunaPath follows what happens next: from early predictions and open-source tools to clinical trials and published outcomes.

Explore the research

From tumor data to vaccine targets

See how sequencing and computational tools narrow tumor-specific changes into candidates for further study.

From prediction to clinical evidence

Understand the difference between a software prediction, a lab result, an immune response, and a clinical outcome.

From research to real-world pathways

Follow the trials, manufacturers, regulators, and access steps that surround each program.

Find your way through a complicated field.

Learn the science, prepare for an oncology conversation, explore costs and expanded access, and see which organizations play each role.

Research and trial landscape
Current papers and trial records, explained in context Open computational tools
See how mutation calling and neoantigen ranking fit into vaccine design Oncology question checklist
Seven questions to bring to a treating team Expanded access
How the FDA pathway works and who needs to be involved Adjustable cost model
Explore the cost categories that can shape a total Organizations by pathway role
See the research centers, labs, manufacturers, and regulators along the path